| Name | Title | Contact Details |
|---|---|---|
Jinhee Chang |
Intellectual Property Counsel | Profile |
Fred Medick |
General Counsel | Profile |
Aviva Gilbert |
Assistant General Counsel, Senior | Profile |
Yan Qi |
Director and Assistant General Counsel, Platforms | Profile |
Sarah Tully |
Director and Assistant General Counsel | Profile |
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.
Centrillion Biosciences is a leading genomic and bioinformatics solution provider.
Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.